Loading…
Employees: 1,116
Size Eckert & Ziegler (EUZ.DE) is a Germany Health Care company (Medical Specialties) with a market value of $969M, the 147th largest of 205 Germany companies the cockpit tracks. Shares closed at €13.80 on 6 Nov 2026.
Performance Over six months the shares fell 7.3%, against -19.2% for the median peer and +2.6% for the Germany market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 4.4% over the last twelve months (peer median +7.3%); the operating margin is 24.8% (peer median 9.5%).
Valuation It trades at 17.0× forward earnings against a peer median of 25.1× (4th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.3 points above its cost of capital (10.6% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €313M | €312M | €296M | €246M | €222M |
| Revenue growth | — | +5% | +20% | +11% | — |
| Gross profit | €152M | €147M | €138M | €111M | €102M |
| EBITDA | €94.8M | €92.1M | €78.7M | €64.5M | €57.8M |
| Net income | €49.7M | €48.8M | €33.3M | €26.3M | €29.3M |
| Free cash flow | €25.5M | €34.4M | €50.4M | €20.7M | €5.92M |
| Capital expenditure | €25.5M | €26.0M | €17.2M | €26.3M | €27.1M |
| Total debt | €41.0M | €44.8M | €55.3M | €56.3M | €49.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EUZ.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.5% | -4.1% | 3rd highest of 21 |
| 6-month return | -7.3% | -19.2% | 8th highest of 21 |
| Distance from 52-week high | -21.0% | -37.3% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.4% | +7.3% | 10th lowest of 21 |
| Operating margin | 24.8% | 9.5% | 3rd highest of 21 |
| Forward P/E | 17.0× | 25.1× | 4th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.2% | 13.1% | 6th least demanding of 14 |
| Growth delivered (Del g) | +12.1% | +12.1% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | -4.9 pp | +8.4 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +16.3 pp | -0.9 pp | 3rd highest of 20 |
| EV / EBITDA | 8.4× | 16.2× | 3rd cheapest of 9 |
| Net debt / EBITDA | -0.7× | -0.9× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |